Cancer vaccines and active immunotherapy

Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies

Volumn , Issue , 2013, Pages 165-180

  Zappasodi, Roberta ^c   Filipazzi, Paola ^a   Rivoltini, Licia ^b   Nicola, Massimo Di ^b  

^a Licia Rivoltini's Unit   (Italy)

^b Istiuto Nazionale dei Tumori   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925123001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.12.127     Document Type: Chapter

References (32)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
2. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non- Hodgkin's lymphomas.N. Engl. J. Med. 311(23), 1471-1475 (1984).
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359(6), 613-626 (2008).
4. Park HJ, Neelapu SS. Developing idiotype vaccines for lymphoma: from preclinical studies to Phase III clinical trials. Br. J. Haematol. 142(2), 179-191 (2008).
5. Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9(9), 675-681 (2009).
6. Brody J, Kohrt H, Marabelle A, Levy R. Active and passive immunotherapy for lymphoma: proving principles and improving results. J. Clin. Oncol. 29(14), 1864-1875 (2011).
7. Sakamaki I, Qin H, Kwak LW. Translational development of vaccination strategies in follicular NHL. BestPract. Res. Clin. Haematol. 24(2),295-304 (2011).
8. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5(10), 1171-1177 (1999).
9. Inoges S, Rodriguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98(18), 1292-1301 (2006).
10. Ai WZ, Tibshirani R, Taidi B, Czerwinski D, Levy R. Phase idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113(23), 5743-5746 (2009).
11. Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11(9), 986-991 (2005).
12. Koc O, Redfern C, Wiernik P et al. Extended follow-up and analysis with central radiological review of patients receiving FavId (Id/KLH) vaccine following rituximab. Blood 106(11), 772 (2005).
13. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumor- derived antigen in first remission improves disease- free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
14. Levy R, Ganjoo M, Leonard K et al. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). American Association for Cancer Research Meeting Abstracts 2008 (Abstract LB-204).
15. Freedman A, Neelapu SS, Nichols C et al. Placebo-controlled Phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.J. Clin. Oncol. 27(18), 3036-3043 (2009).
16. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220, 129-150 (2007).
17. Timmerman JM. Idiotype- pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5), 1517-1526 (2002).
18. Di Nicola M, Zappasodi R, Carlo-Stella C et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113(1), 18-27 (2009).
19. Zappasodi R, Pupa SM, Ghedini GC et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res. 70(22), 9062-9072 (2010).
20. Neelapu SS, Baskar S, Gause BL et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res. 10(24), 8309-8317 (2004).
21. 21 Neelapu SS, Gause BL, Harvey L et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12), 5160-5163.2007
22. Neelapu SS, Gause BL, Harvey L et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109(12), 5160-5163.2007
23. Zitvogel L, Apetoh L, Ghiringhelli FO, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 2008
24. Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28, 4324-4332 (2010).
25. Gascoyne RD, Rosenwald A, Poppema S, Lenz G.Prognostic biomarkers in malignant lymphomas. Leuk. Lymphoma 51(Suppl. 1),11-19 (2010).
26. Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr. Opin. Oncol. 22(5), 424-430 (2010).
27. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 115, 289-295 (2010).
28. Wilcox RA, Ristow K, Habermann TM et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk. Lymphoma 53(4), 575-580 (2012).
29. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low|/- monocytes in B-cell non-Hodgkin lymphoma. Blood 117(3), 872-881 (2011).
30. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte- macrophage colony- stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25(18), 2546-2553 (2007).
31. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 113(15), 3546-3552 (2009).
32. Noonan K, Rudraraju L. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin. Cancer Res.18, 1426-1434 (2012).